What are ADC's

Our services

ADC Review
is made possible by:


Study Title
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma (NCT02275598)

Trial Description
The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg brentuximab vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).

In this trial, treatment with the antibody-drug conjugate brentuximab vedotin is followed with the standard ABVD regimen, a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine) which was developed in the early 1970’s as an alternative to MOPP (mechlorethamine, vincristine, procarbazine and prednisone).  The MOPP regimen was first combination regimen for the treatment of Hodgkin’s disease developed in 1964 by researchers at the National Cancer Institute.

This trial is sponsored by University of Modena and Reggio EmiliaMillennium Pharmaceuticals. [1]

Study Data

Study Schematic

(Coming soon)Screen Shot 2016-07-18 at 4.46.40 PM

Click here to Return to Drug map

Last Editorial review: July 18, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar